What Vaniam Group does

Vaniam Group is a privately held, woman-owned oncology organization founded in 2007 that provides consulting, scientific communication, expert engagement, and insights-gathering services to biopharmaceutical companies. The firm operates as a platform-plus-modules architecture, with three core operating subsidiaries: Bio Ascend (medical education for oncology, hematology, cell therapy, rare disease, and immunology), Curio Science (subscription intelligence platform connecting a network of 14,000+ HCPs and patients), and Women Leaders in Oncology (community organization and Young Investigator Awards program). It is staffed by 251-500 specialists distributed across the United States in a fully virtual operating model registered at a single Chicago headquarters.

The firm's central technology is Vaniam Intelligence, a proprietary AI platform launched in May 2025 and built exclusively on twenty years of longitudinal oncology engagement data accumulated through Curio Science. The platform supports predictive analytics (including the Predictive Pathways module for forecasting market shifts 60-90 days ahead), knowledge retrieval, generative insights, and workflow automation for biopharma medical affairs and commercial teams. The data asset is engagement-derived rather than assembled from external sources, and the platform is positioned as purpose-built rather than adapted from general-purpose technology.

Vaniam Group generates revenue through four streams: project-based medical communications services (publications, advisory boards, congress programming, MSL resources, KOL engagement); Curio Science subscriptions providing longitudinal HCP and patient insights; Bio Ascend medical education programs developed with accredited CME providers; and Vaniam Intelligence enterprise licensing. Pricing is not publicly disclosed and is quote-based for custom solutions. The go-to-market is enterprise field sales targeted at biopharma medical affairs and commercial teams, supplemented by subscription inside-sales for Curio Science and an event-driven presence at major oncology congresses, particularly ASCO. The firm is WBENC-certified, holds an EcoVadis Platinum sustainability rating (top 1% globally), and has appeared on the Inc. 5000 list across multiple consecutive years.

Name

Vaniam Group

Legal name

Vaniam Group LLC

Website

https://vaniamgroup.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Vaniam Group is a privately held, woman-owned oncology organization providing scientific communications, medical education, and AI-powered intelligence services to biopharmaceutical companies. It operates Bio Ascend (education), Curio Science (14,000+ HCP subscription platform), and Vaniam Intelligence (proprietary AI for oncology strategy).

Ownership category

akta.pro rank

Product category

Oncology Medical Communications & Biopharma Intelligence

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Oncology medical communications
• Biopharma intelligence platform
• Healthcare provider insights
• Patient engagement services
• Oncology medical education

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Medical Communications Services: Full-service medical communications including publications, scientific platforms, advisory boards, congress programming, MSL resources, scientific exchange, and thought leader engagement. Revenue derived from project-based engagements with biopharma medical affairs and commercial teams.
2. Curio Science Subscription: Subscription-based oncology intelligence platform providing longitudinal insights from a network of 14,000+ HCPs. Biopharma clients subscribe for access to curated insights, analytics, and strategic intelligence.
3. Bio Ascend Medical Education: Medical education programs including CME activities developed in partnership with accredited providers and non-CME scientific education programs. Revenue from biopharma medical affairs teams, foundations, and academic institutions.
4. Vaniam Intelligence Platform Access: Access to AI-powered analytics platform with configurable, scalable insights for biopharma strategic decision-making. Platform features including Predictive Pathways are delivered through enterprise licensing arrangements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Vaniam Group delivers oncology-focused medical communications, medical education, patient engagement, and AI-powered intelligence services to biopharma companies. Its offerings include scientific platforms, publications, advisory boards, congress programming, KOL engagement, MSL resources, and a proprietary AI platform (Vaniam Intelligence) built on 20 years of longitudinal insight from a 14,000+ HCP network. The company also operates Curio Science (subscription HCP/patient intelligence), Bio Ascend (medical education), and Vaniam Patient Network.

Product overview

Vaniam Group is an integrated oncology organization operating as a platform-plus-modules architecture. The core platform is Vaniam Intelligence, a proprietary AI system powered by longitudinal oncology insight from 20 years of engagement. This platform is enhanced by Predictive Pathways, a forecasting capability. Vaniam Group's portfolio includes Curio Science (HCP/patient subscription intelligence with 14,000+ HCP network), Bio Ascend (medical education), Women Leaders in Oncology (community/awards), Patient Engagement services, and Vaniam Patient Network. These components work together: Curio Science generates the proprietary data that feeds Vaniam Intelligence, which then delivers actionable insights across the organization's medical communications and patient engagement services.

Differentiator

Problem solved

Functional benefit

Brands

• Vaniam Intelligence™: Purpose-built AI platform integrating proprietary artificial intelligence with human expertise to transform biopharma strategy and decision-making.
• Predictive Pathways
• Vaniam Patient Network™
• Women Leaders in Oncology®
• Bio Ascend™
• Curio Science

Products and services

• Vaniam Intelligence Purpose-built AI platform powered by proprietary longitudinal oncology insight that integrates data, strategic insights, and advanced analytics to help biopharma teams make confident decisions from clinical development to commercialization.
• Curio Science Subscription intelligence platform connecting HCPs and patients through scientifically rigorous engagement to generate longitudinal oncology insights, with a network of 14,000+ HCPs.
• Bio Ascend Medical Education Medical education company specializing in oncology, hematology, cell therapy, rare disease, metabolic disorders, and immunology. Designs scientific education for clinicians at conferences and academic settings, including CME and non-CME programs developed with accredited providers and biopharma medical affairs teams.
• Patient Engagement Services Partnership with patients and caregivers to shape drug development from earliest stages through commercialization, including patient insights, content co-creation, digital engagement, and advocacy programs.
• Vaniam Patient Network Network connecting individuals living with or caring for someone with health challenges to drive innovation in patient care and treatment development, with compensation for engagement; covers breast, lung, prostate, colorectal, pancreatic, ovarian cancers, hematologic malignancies, and rare diseases.
• Medical Communications Full spectrum of scientific communications, medical affairs support, and creative execution including strategy, narrative, publications, congress programming, advisory boards, KOL engagement, scientific platforms, and MSL resources for biopharma clients.
• Customizable Intelligence Solutions AI-enabled framework providing configurable, scalable intelligence solutions designed to turn oncology insight into actionable clarity for biopharma teams.

Quantifiable outcome

• 14,000+ HCPs in Curio Science network generating longitudinal oncology insights
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core and minor.

• World Health CommunicationscoreStrategic or Co-development Partner · 4 June 2026Strategic transition in which Bio Ascend, Vaniam Group's medical education company, assumes stewardship of the International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma). These are leading forums in hematologic oncology. Dr. Stuart W. G. Smith will continue collaborating with the new leadership to guide continued evolution and global expansion. Bio Ascend takes primary responsibility for organization, delivery, and future development.
• Conquer Cancer (ASCO Foundation)coreStrategic or Co-development Partner · 30 May 2025Partnership to present Young Investigator Awards at ASCO Annual Meeting. Vaniam Group and Women Leaders in Oncology fund awards through Conquer Cancer, the ASCO Foundation. Awards support early-career physician-scientists advancing oncology research. Vaniam Group CEO Deanna B. van Gestel serves as Board Member of Conquer Cancer.
• Academy of Next Wave of InvestigatorscoreStrategic or Co-development Partner · 10 June 2024Bio Ascend-led program convening young clinical investigators for year-long mentorship through professional development led by international thought leaders. Faculty includes renowned oncologists from Johns Hopkins, Emory University, MD Anderson, Memorial Sloan Kettering, and other leading institutions. 18 investigators selected for 2024-2025 class in thoracic oncology.
• Accredited CME ProviderscoreStrategic or Co-development PartnerBio Ascend develops accredited educational activities in partnership with accredited CME providers—academic medical centers and independent accredited education companies. Programs are designed, delivered, and evaluated in accordance with standards of accrediting partners.
• Patient Advocacy OrganizationsminorStrategic or Co-development PartnerPartnerships with patient advocacy organizations to build and facilitate ambassador and mentor programs, strengthen networks, elevate community voices, and ensure strategies are rooted in lived experiences.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Beghou Consulting: Specialized life sciences consulting firm focused on commercial strategy, analytics, and forecasting for biopharma; comparable in target customers and data-driven decision support.
• Inizio Evoke: Global health and wellness communications and advisory platform serving biopharma with medical communications, transformation, and patient engagement services; comparable as a scaled oncology-adjacent peer.
• Real Chemistry: Data-driven healthcare communications and marketing agency combining proprietary data, AI, and creative services for biopharma clients; directly comparable in blending scientific communications with proprietary intelligence and AI tooling.
• OPEN Health Group: Global medical communications and biopharma services group that explicitly acquired Cherie Myatt's former CM Group, making it the closest direct peer to Vaniam Group in oncology-focused medical communications, patient engagement, and strategic consulting.
• Trinity Life Sciences: Biopharma strategic intelligence and consulting firm offering primary market research, advanced analytics, and commercial strategy for oncology and rare disease; comparable as a subscription-and-advisory intelligence provider to biopharma.
• Precision Medicine Group: Specialized biopharma services platform covering medical communications, market access, and commercial strategy with strong oncology presence; comparable in target customers, therapeutic focus, and integrated service model.
• EVERSANA: Independent life sciences commercialization services company providing medical affairs, patient services, and data-driven commercial strategy for biopharma; comparable in oncology and rare disease focus with bundled service offerings.
• Fishawack Health (Avalere): Global biopharma commercialization and medical communications organization with deep oncology capability; comparable in scientific communications, publications, and KOL engagement offerings.

Broad incumbents

• Publicis Health: Global healthcare communications network serving biopharma, payers, and providers with creative, medical, and data capabilities; competes with Vaniam on enterprise oncology medical communications engagements.
• Omnicom Health Group: Largest healthcare communications holding company with multiple agencies serving biopharma in oncology and other therapeutic areas; broader portfolio and not oncology-specialized but competes for the same enterprise medical affairs and medical communications RFPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/VaniamGroup
• LinkedInlinkedin.com/company/vaniam-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaniam Group